Company Profile
KALA BIO Stock Price, News & Analysis
- Ticker:
- KALA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.84 USD (+11.91%)
Close
Last updated: August 11, 2026
44.4M USD
Market cap
Why the stock is moving
As of Aug 11, 2026, KALA closed up 11.9% at $0.8449. No new same-company headline was identified in the current news window.
Company overview
Business overview
KALA BIO is an eye-care biotechnology company focused on corneal and ocular surface disease. Its story centers on developing therapies for chronic ophthalmic conditions with limited treatment options.
Geographic Base and Sector Classification
KALA BIO is headquartered in the United States and listed on NASDAQ. It sits in ophthalmology biotechnology.
Business Model Characteristics
The company depends on clinical progress, regulatory milestones, and the ability to commercialize a focused eye-care pipeline. Investors watch data, safety, and access strategy.
Position Within the Biotechnology Landscape
KALA occupies a niche ophthalmology position within biotech. It is catalyst-sensitive because eye-disease programs often hinge on a narrow set of data events.
Future catalysts
- KALA Bio is largely a legacy / closeout story, so the catalysts are any remaining strategic or asset-resolution update. There is no live standalone growth story left.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of KALA BIO (KALA)?
KALA BIO (KALA) most recently closed at 0.84 USD, a +11.91% move versus the previous session.
What is the market cap of KALA BIO (KALA)?
KALA BIO currently has a market capitalization of 44.4M USD on BioPharmSignal.
What does KALA BIO do?
KALA BIO is an eye-care biotechnology company focused on corneal and ocular surface disease. Its story centers on developing therapies for chronic ophthalmic conditions with limited treatment options.
On which exchange is KALA stock listed?
KALA BIO (KALA) is associated with NASDAQ, United States, Biopharma.
What is There?
There is no live standalone growth story left.
Which conditions is KALA BIO targeting with There?
There is no live standalone growth story left.
How does KALA BIO describe recent progress with There?
There is no live standalone growth story left.
What future catalysts are investors watching for KALA BIO?
KALA Bio is largely a legacy / closeout story, so the catalysts are any remaining strategic or asset-resolution update. There is no live standalone growth story left.